A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
17/02/2022at 09:51

Genmab CEO: Tivdak launch has provided important experience for future treatments

The launch of Tivdak in the US, which is currently taking place, is providing Genmab with important experiences ahead of the launch of epcoritamab with partner Abbvie later this year, says company CEO Jan van de Winkel.
Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH
by andreas lønstrup, translated by catherine brett

Tivdak, which was approved as a cervical cancer treatment in the US last year, is the first drug that Danish biotech company Genmab has chosen to sell and market itself.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Joost Melis / Genmab / PR

    Analyst ahead of Genmab report: Focus will be on Darzalex prognosis

    For subscribers

  • Jan van de Winkel, CEO at Genmab | Photo: Stine Bidstrup/Ritzau Scanpix

    Abbvie to submit first Genmab collaboration candidate in 2022

    For subscribers

  • Photo: Tuala Hjarnø / Genmab / PR

    Janssen submits Genmab-developed drug for EMA approval

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Anders Heering, editor-in-chief, Watch Media | Foto: Philip Hoepner
Other

Welcome to the new MedWatch

An uncompromising focus on quality journalism has made Watch Media a rising star in Nordic business journalism. A new design will strengthen the user experience on MedWatch and our other media.
Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Foto: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

After a research breakthrough, the Danish firm is ready to mature – meaning that Jesper J. Lange can’t both be chief executive and a board member.

For subscribers

Foto: Pr/dnb
Pharma & biotech

DNB Markets recommends to sell Genmab stock

The Norwegian investment bank also lowers its share price target for the Danish biotech company, arguing that analysts are overestimating 2023 sales expectations.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Head of International Sales

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Commercial Director

  • Clinical Operational Associate

See all jobs

Jobs

  • Head of International Sales

  • Senior Regulatory Affairs Professional

  • Head of Regulatory Affairs Danmark

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Principal Laboratory Technologist

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Experienced Patent Counsel

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Commercial Director

  • Clinical Operational Associate

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge